A Phase 1 interventional study of Ensitrelvir in Healthy Adult Female Participants, sponsored by Shionogi. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-04.
Sponsored by Shionogi · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to examine the potential for drug-drug interactions.
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
A female participant is eligible to participate if she is not pregnant or breastfeeding, and either of the following conditions applies:
Key Exclusion Criteria:
NOTE: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive multiple oral doses of a combined oral contraceptive (COC) (EE and DRSP) once daily for 24 days (Days 1 to 24) (in the fasted state on Days 18 to 24) in the morning. Participants will also receive ensitrelvir high dose on Day 20 and multiple oral doses of ensitrelvir low dose once daily on Days 21 to 24 in the fasted state.
Drug: Ensitrelvir
Ensitrelvir will be administered per schedule specified in the arm description.
Also known as: S-217622
Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol (EE)
Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
Cmax of Drospirenone (DRSP)
Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
Time to Reach Cmax (Tmax) of EE
Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
Tmax of DRSP
Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC0-τ) of EE
Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
AUC0-τ of DRSP
Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
Number of Participants With Adverse Events (AEs)
Time frame: Day 1 up to Day 32
Cmax of Ensitrelvir
Time frame: Predose and up to 24 hours postdose on Days 20 and 24
Tmax of Ensitrelvir
Time frame: Predose and up to 24 hours postdose on Days 20 and 24
AUC0-τ of Ensitrelvir
Time frame: Predose and up to 24 hours postdose on Days 20 and 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Apr 2025, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensitrelvir